<DOC>
	<DOCNO>NCT01530607</DOCNO>
	<brief_summary>This phase III trial LHRH analog administration chemotherapy reduce ovarian failure follow chemotherapy early stage , hormone-receptor negative breast cancer .</brief_summary>
	<brief_title>Administration During Chemotherapy Reduce Ovarian Failure Following Chemotherapy Early Stage , Hormone-Receptor Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>1 . Patients must premenopausal woman histologically confirm diagnosis operable Stage I , II , IIIA invasive breast cancer . Patients complete surgery must pathologic Stage I , II , IIIa disease . Patients treat preoperative setting may stag clinically must operable disease . For purpose study , premenopausal define presence cyclic menstrual bleeding within 6 week prior randomization documentation FSH estradiol level premenopausal range . 2 . Patients must tumors estrogen receptor negative progesterone receptor negative . 3 . Patients must age 18 great age 50 . 4 . The patient 's plan treatment must include 3 8 month cycle alkylating agent contain postoperative preoperative chemotherapy regimen anthracyclinebased nonanthracyclinebased . 5 . For patient receive chemotherapy preoperative setting , must intention give additional chemotherapy postoperative set 6 . Patients receive postoperative chemotherapy must register within 84 day final surgical procedure require adequately treat primary tumor axilla . 7 . Patients must receive prior cytotoxic chemotherapy breast cancer condition . Patients currently enrol S0221 eligible study . 8 . Patients must receive estrogen , antiestrogens , selective estrogen receptor modulators , aromatase inhibitor , hormonal form contraception within past month follow exception : Women age 35 may recent use oral contraceptive pill must discontinue prior randomization . In addition , woman age , two month hormonal treatment oocyte collection purpose vitro fertilization cryopreservation embryo oocyte permit provided treatment complete prior randomization . Women use oral contraceptive pill hormonal treatment oocyte collection month prior enrollment must documentation FSH estradiol level premenopausal range . 9 . No prior malignancy allow except adequately treat basal cell ( squamous cell ) skin cancer , situ cancer cancer patient diseasefree five year treatment curative intent . 10 . Patients must performance status 0 2 Zubrod criterion ( see Section 10.4 ) . 11 . Pregnant nursing woman may participate due possibility fetal harm harm nursing infant treatment regimen . Women reproductive potential must agree use effective barrier contraceptive method . 13 . All patient must inform investigational nature study must sign give write informed consent accordance institutional federal guideline .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Early Stage Breast Cancer</keyword>
	<keyword>Reduce Ovarian Failure Following Chemotherapy</keyword>
</DOC>